Northern Trust Corp increased its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 4.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,048,694 shares of the medical equipment provider’s stock after purchasing an additional 45,134 shares during the quarter. Northern Trust Corp owned 1.26% of Accuray worth $4,981,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Accuray by 4.6% during the first quarter. Vanguard Group Inc. now owns 6,447,130 shares of the medical equipment provider’s stock valued at $30,623,000 after purchasing an additional 286,011 shares in the last quarter. Lapides Asset Management LLC lifted its holdings in shares of Accuray by 0.3% during the second quarter. Lapides Asset Management LLC now owns 2,221,300 shares of the medical equipment provider’s stock valued at $10,551,000 after purchasing an additional 7,500 shares in the last quarter. Royce & Associates LP lifted its holdings in shares of Accuray by 6.7% during the second quarter. Royce & Associates LP now owns 1,676,077 shares of the medical equipment provider’s stock valued at $7,961,000 after purchasing an additional 105,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Accuray by 27.6% during the first quarter. Dimensional Fund Advisors LP now owns 858,013 shares of the medical equipment provider’s stock valued at $4,076,000 after purchasing an additional 185,519 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Accuray by 13.4% during the second quarter. Russell Investments Group Ltd. now owns 773,480 shares of the medical equipment provider’s stock valued at $3,673,000 after purchasing an additional 91,267 shares in the last quarter. 75.47% of the stock is currently owned by hedge funds and other institutional investors.

In other Accuray news, COO Kelly Londy sold 99,136 shares of the stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $4.24, for a total value of $420,336.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 3.90% of the stock is currently owned by corporate insiders.

Accuray Incorporated (NASDAQ ARAY) opened at $4.80 on Friday. Accuray Incorporated has a 1-year low of $3.60 and a 1-year high of $6.00. The company has a quick ratio of 0.92, a current ratio of 1.48 and a debt-to-equity ratio of 2.44.

Accuray (NASDAQ:ARAY) last posted its earnings results on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. The company had revenue of $91.00 million for the quarter, compared to the consensus estimate of $88.26 million. During the same quarter in the prior year, the company earned ($0.12) earnings per share. Accuray’s revenue was up 5.2% on a year-over-year basis. equities analysts anticipate that Accuray Incorporated will post -0.18 EPS for the current year.

WARNING: “Northern Trust Corp Has $4.98 Million Holdings in Accuray Incorporated (ARAY)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/19/northern-trust-corp-has-4-98-million-holdings-in-accuray-incorporated-aray.html.

ARAY has been the topic of a number of research analyst reports. Zacks Investment Research downgraded Accuray from a “hold” rating to a “strong sell” rating in a report on Monday, July 24th. BidaskClub downgraded Accuray from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Jefferies Group LLC reaffirmed a “buy” rating and set a $7.00 price target on shares of Accuray in a report on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $5.00 price target on shares of Accuray in a report on Thursday, August 24th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Accuray in a report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $6.29.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Stock Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related stocks with our FREE daily email newsletter.